Top Page
JCR Pharmaceuticals Co., Ltd.
(4552)
JCR Pharmaceuticals Co., Ltd. (4552) vs. iShares MSCI Japan ETF (EWJ)
JCR Pharmaceuticals Co., Ltd. Business Overview & Revenue Model
JCR Pharmaceuticals Co., Ltd. Financial Statement Overview
| Breakdown | |||||
| TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 35.03B | 42.87B | 34.34B | 51.08B | 30.09B | 24.78B | Gross Profit |
| 24.61B | 31.25B | 25.46B | 40.62B | 22.27B | 16.88B | EBIT |
| -1.25B | 7.53B | 4.97B | 19.93B | 8.27B | 3.24B | EBITDA |
| 2.45B | 10.53B | 6.97B | 21.88B | 10.18B | 4.68B | Net Income Common Stockholders |
| -228.00M | 5.51B | 3.77B | 14.51B | 6.89B | 2.68B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 18.76B | 18.76B | 13.28B | 30.98B | 26.26B | 11.19B | Total Assets |
| 102.23B | 102.23B | 94.94B | 97.13B | 73.78B | 47.77B | Total Debt |
| 23.30B | 23.30B | 22.80B | 18.10B | 18.10B | 8.76B | Net Debt |
| 4.54B | 4.54B | 9.52B | -12.63B | -8.16B | -2.22B | Total Liabilities |
| 45.75B | 45.75B | 42.52B | 46.05B | 35.23B | 15.20B | Stockholders Equity |
| 56.18B | 56.18B | 52.16B | 50.88B | 38.38B | 32.39B |
| Cash Flow | Free Cash Flow | ||||
| 0.00 | 7.22B | -14.06B | -2.04B | 2.81B | 89.00M | Operating Cash Flow |
| 0.00 | 9.31B | -5.50B | 9.29B | 10.34B | 4.93B | Investing Cash Flow |
| 0.00 | -2.69B | -15.00B | -3.25B | -3.29B | -4.16B | Financing Cash Flow |
| 0.00 | -2.03B | 1.95B | -2.18B | 8.30B | 2.05B |
JCR Pharmaceuticals Co., Ltd. Technical Analysis
JCR Pharmaceuticals Co., Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
87 Outperform | $2.07T | 11.75 | 12.99% | 2.67% | 1.58% | 12.48% | |
79 Outperform | $12.36T | 30.15 | 22.80% | 1.27% | 17.96% | 25.65% | |
70 Outperform | ¥2.51T | 49.14 | 3.22% | 5.19% | 19.25% | 294.48% | |
68 Neutral | $6.57T | 60.68 | 1.50% | 4.94% | 9.83% | 15.49% | |
65 Neutral | $1.12T | 24.27 | 5.34% | 3.82% | 5.63% | 30.61% | |
53 Neutral | ¥55.81B | ― | 4.37% | -15.31% | -104.20% | ||
53 Neutral | $5.14B | 3.03 | -43.89% | 2.83% | 16.75% | -0.06% |
JCR Pharmaceuticals Co., Ltd. Corporate Events
JCR Pharmaceuticals Co., Ltd. announced the nomination of new candidates for its Audit & Supervisory Board, with appointments to be confirmed at the upcoming Ordinary General Meeting of Shareholders. This change reflects a strategic move to refresh its governance structure, potentially impacting its operational oversight and stakeholder confidence.
JCR Pharmaceuticals has revised its full-year consolidated earnings forecast for FY2024, anticipating significant financial losses due to an unfinalized licensing agreement and increased costs in sales and R&D. The company expects an operating loss of 6 billion yen and a loss attributable to owners of 4.3 billion yen, as extraordinary income from a government subsidy will not be realized this fiscal year. These adjustments reflect challenges in JCR’s financial performance, impacting its market positioning and stakeholder expectations.
JCR Pharmaceuticals Co., Ltd. announced changes in corporate officer duties, organizational structure, and personnel to enhance strategic decision-making and strengthen operations. The reorganization includes the establishment of a new Kinki Sales Department and a Distribution Measures Department, reflecting JCR’s commitment to improving operational efficiency and market responsiveness.
JCR Pharmaceuticals has commenced construction of a new drug product plant at the Kobe Science Park Center, aimed at enhancing its vaccine production capabilities in pandemic emergencies. The project, supported by government subsidies, will integrate with an existing API plant to strengthen JCR’s manufacturing capacity, although it is expected to have a minor impact on the company’s financial results for the current fiscal year.
JCR Pharmaceuticals is proudly supporting Rare Disease Day 2025 in Japan, an event dedicated to raising awareness about rare diseases. The company is organizing several initiatives, including a keynote session by its Executive Director, an awareness campaign, and educational displays. JCR is committed to improving the lives of patients with rare diseases through enhanced awareness, reflecting its dedication to patient care and community engagement.
JCR Pharmaceuticals Co., Ltd. announced a correction to their previously released FY2024 Third Quarter Consolidated Financial Results Conference Call Material. While the specific corrections are not detailed, such amendments are crucial for maintaining transparency and accuracy in financial communications, which could impact stakeholder trust and the company’s market positioning.
JCR Pharmaceuticals announced the presentation of promising data from its investigational therapies for lysosomal storage disorders at the WORLDSymposium™ 2025. The presentations highlighted the potential of their J-Brain Cargo® technology, with evidence showing that JR-141 has long-term safety and efficacy for MPS II, while JR-479 demonstrated positive non-clinical results for GM2 gangliosidoses. These advancements could strengthen JCR’s position in the market and potentially offer new treatment options for these challenging conditions.